TRACON Pharmaceuticals, Inc.
TCON · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $12,045 | $0 | $346 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $14 | $16 | $14 | $12 |
| Gross Profit | $12,031 | -$16 | $332 | -$12 |
| % Margin | 99.9% | – | 96% | – |
| R&D Expenses | $12,277 | $13,888 | $11,146 | $8,198 |
| G&A Expenses | $6,666 | $14,006 | $17,547 | $8,025 |
| SG&A Expenses | $6,666 | $14,006 | $17,547 | $8,025 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$7 |
| Operating Expenses | $18,929 | $27,894 | $28,693 | $16,223 |
| Operating Income | -$6,898 | -$27,894 | -$28,347 | -$16,223 |
| % Margin | -57.3% | – | -8,192.8% | – |
| Other Income/Exp. Net | $3,310 | -$1,241 | -$320 | -$552 |
| Pre-Tax Income | -$3,588 | -$29,135 | -$28,667 | -$16,775 |
| Tax Expense | $0 | $177 | $0 | $551 |
| Net Income | -$3,588 | -$29,312 | -$28,726 | -$17,326 |
| % Margin | -29.8% | – | -8,302.3% | – |
| EPS | -2.2 | -28.02 | -33.3 | -38.63 |
| % Growth | 92.1% | 15.9% | 13.8% | – |
| EPS Diluted | -2.19 | -28.02 | -33.3 | -38.57 |
| Weighted Avg Shares Out | 1,631 | 1,046 | 863 | 449 |
| Weighted Avg Shares Out Dil | 1,637 | 1,046 | 863 | 449 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $994 | $0 | $545 |
| Interest Expense | $7,304 | $994 | $318 | $545 |
| Depreciation & Amortization | $14 | $16 | $14 | $12 |
| EBITDA | -$6,884 | -$28,125 | -$28,333 | -$16,223 |
| % Margin | -57.2% | – | -8,188.7% | – |